Show simple item record

dc.contributor.authorTukenmez, Mustafa
dc.contributor.authorMuslumanoglu, Mahmut
dc.contributor.authorIgci, Abdullah
dc.contributor.authorDinccag, Ahmet
dc.contributor.authorOzmen, Vahit
dc.contributor.authorAydiner, Adnan
dc.contributor.authorYavuz, Ekrem
dc.contributor.authorCabioglu, Neslihan
dc.contributor.authorOner, Gizem
dc.contributor.authorOnder, Semen
dc.contributor.authorKaratay, Huseyin
dc.contributor.authorAk, Naziye
dc.date.accessioned2021-12-10T13:19:02Z
dc.date.available2021-12-10T13:19:02Z
dc.date.issued2021
dc.identifier.citationOner G., Onder S., Karatay H., Ak N., Tukenmez M., Muslumanoglu M., Igci A., Dinccag A., Ozmen V., Aydiner A., et al., "Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy", WORLD JOURNAL OF SURGICAL ONCOLOGY, cilt.19, sa.1, 2021
dc.identifier.issn1477-7819
dc.identifier.othervv_1032021
dc.identifier.otherav_fe3ddf6b-6496-4d27-a46c-f2eaa4024e0a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/175905
dc.identifier.urihttps://doi.org/10.1186/s12957-021-02361-9
dc.description.abstractBackground Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and patient survival. Methods PD-L1 expression was evaluated immunohistochemically (Ventana SP263 clone kit) by staining tumor specimen. PD-L1 positivity was defined as membranous staining > 1%, > 5%, > 10%, and > 20% on either tumor cell (TC) and /or immune cell (IC). Results Fifty patients with locally advanced TNBC, who had a partial response to NACT, were included in the study. PD-L1 staining was observed in TCs in 25 patients (50%) and in ICs in 23 patients (46%) when PD-L1 > 1% was considered positive. Patients with PD-L1 positivity on ICs were more likely to respond to chemotherapy as measured by "MD Anderson Cancer Center Residual Cancer Burden Index" (14/22, 63.6% vs. 10/27, 37%, p = 0.064). The 5-year disease-free survival (DFS) and disease-specific survival (DSS) rates were 46.3% and 51.4%, respectively. A high (> 20%) tumoral PD-L1 positivity was associated with a better DFS and DSS. Conclusions Studies in the literature mostly focused on PD-L1 expression in inflammatory cells. However, our results suggest that patients with a high PD-L1 expression on TCs were more likely to have a better outcome. Since patients with residual tumor burden who express PD-L1 on TILs were more likely to respond to NACT, an immune checkpoint inhibitor therapy in addition to NACT would be an important option for TNBC with locally advanced disease.
dc.language.isoeng
dc.subjectSurgery
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectCERRAHİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleClinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
dc.typeMakale
dc.relation.journalWORLD JOURNAL OF SURGICAL ONCOLOGY
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Genel Cerrahi Ana Bilim Dalı
dc.identifier.volume19
dc.identifier.issue1
dc.contributor.firstauthorID2725209


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record